# Astromech AI

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/astromech-ai

- Industry: Biotechnology
- Headquarters: Austin, US
- Website: www.astromech.com/
- Total disclosed funding: $11M
- Latest round: Seed (Mar 12, 2026)
- Investors on record: 1

## About

Astromech AI, Corp., founded in 2025 and based in the Texas, US, offers advanced artificial intelligence solutions that integrate multi-dimensional biological insights, enhancing research capabilities in genomics and biotechnology. 

Founded in 2025 and based in Texas, US, Astromech AI, Corp., specializes in AI-driven genomic analysis. Astromech specializes in AI-driven genomic analysis. The company was co-founded by Ben Lamm and George Church. In August 2026, Astromech AI, Corp. raised USD 20 million in venture funding led by an individual investor, with participation from new investors NeoGenesis Capital, PEAK6 Investments, and CAZ Investments. Returning investor Builders VC and individual investor also participated in the round.

Astromech is advancing the fields of AI and biology with a robust platform designed to integrate multi-dimensional biological insights through state-of-the-art AI technologies. Central to their offerings are advanced systems for genomic inference, including Attention-Based Deep Learners that identify functional patterns across diverse transcriptomes, and Bayesian Ancestral Reconstruction tools that compute evolutionary trajectories. The company also focuses on a Graph-Based Pangenome to capture population-scale structural variants and is developing a Multi-Omics Integrator to provide unified insights across complex biological systems. These solutions are tailored for a variety of end users, including scientists, researchers, and engineers in medicine and agriculture, aiming to enhance their understanding of genetic information and its applications in a range of fields. The primary markets for Astromech's products span North America, Europe, and Asia, catering to both academic institutions and private sector organizations engaged in cutting-edge biological research. 

Astromech generates revenue through a subscription-based model, allowing clients to access its suite of AI-driven genomic analysis tools, which include flagship offerings like the Attention-Based Deep Learner and Bayesian Ancestral Reconstruction systems. The pricing structure typically involves tiered subscription plans, enabling clients to select services based on their specific research needs and scale of operation. Partnerships with organizations in life sciences, biotechnology, and agricultural sectors further enhance the company’s revenue streams by facilitating collaborative projects that leverage shared resources and expertise. Transactions are primarily conducted on a B2B basis, with clients ranging from research institutions to biotech firms, driving a steady flow of income through the utilization of advanced tools for genomic synthesis and analysis. 

The company plans to use the August 2026 funding to expand its research team, add more species to its genomic datasets, and scale the infrastructure used to train its biological prediction models.

## Funding rounds

- Seed, Mar 12, 2026, $11M — Builders VC

## Investors

- Builders VC (https://capitalatlas.ai/funds/builders-vc) — Seed